Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May;22(5):928-31.
doi: 10.1038/cr.2012.27. Epub 2012 Feb 21.

Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers

Fei Li, Yan Feng, Rong Fang, Zhaoyuan Fang, Jufeng Xia, Xiangkun Han, Xin-Yuan Liu, Haiquan Chen, Hongyan Liu, Hongbin Ji
Free PMC article

Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers

Fei Li et al. Cell Res. 2012 May.
Free PMC article
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Identification of CCDC6-RET fusion in the “pan-negative” lung adenocarcinomas from never smokers and the construction of a more comprehensive spectrum of oncogenic drivers in this subset of lung cancer. (A) Exon array analyses of 5 samples “pan-negative” for oncogenic drivers and 12 samples with known oncogenic drivers have identified a potential RET fusion in lung cancer sample 181LC. The potential fusion point is indicated by yellow arrow. (B) 5′ RACE analyses of the “pan-negative” lung cancer sample 181LC showed a PCR band about 1.4 kb, which is obviously different from the wild-type RET band (about 960 bp). (C) Sequencing result confirmed the CCDC6-RET fusion in lung cancer sample 181LC. (D) Long-range PCR detection of the genomic breakpoint of CCDC6-RET fusion in lung cancer sample 181LC. (E) Sequencing result showed the detailed genomic breakpoint of CCDC6-RET fusion in lung cancer sample 181LC. (F) A more comprehensive spectrum of oncogenic drivers is constructed for the cohort containing 52 lung adenocarcinomas from never smokers. (G) Detection of CCDC6-RET fusion in 24 “pan-negative” samples identified from the 202 lung adenocarcinomas from never smokers. Except for lung cancer sample 181LC, 261LC also harbors the CCDC6-RET fusion. LC: lung cancer. NL: normal lung.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Toh CK, Gao F, Lim WT, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol. 2006;24:2245–2251. - PubMed
    1. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 2007;25:561–570. - PubMed
    1. Herbst RS, Lippman SM. Molecular signatures of lung cancer--toward personalized therapy. N Engl J Med. 2007;356:76–78. - PubMed
    1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139. - PubMed
    1. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005;23:2556–2568. - PubMed

Publication types